COVID-19: ABC System and LBP-like Function of ORF7a Activate Monocytes to Induce Diabetes

22 June 2021, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


Lipopolysaccharide activates the natural immune system response in obese and diabetic patients’ adipose tissue and increases the risk of susceptibility and severity of COVID-19. In this study, bioinformatics techniques such as domain search and molecular docking were used to study the relationship between the ORF7a protein of the SARS-COV-2 virus and lipopolysaccharide. The results show that the transmembrane protein ORF7a has ABC transporter domains: ATP binding and ABC transmembrane domains. ORF7a also has lipopolysaccharide synthesized domains. It bound the lipopolysaccharide synthesized by ORF7a to CD14 molecule through lipopolysaccharide-binding protein (LBP) to activate CD14+ monocytes. The extracellular ORF7a with the N-terminus and C-terminus cut off has a similar function of LBP, binding and activating CD14+ monocytes with the help of two ATP-binding structures. We speculated that more lipopolysaccharides also activated CD14+ monocytes to release various inflammatory factors, damaging adipose and vascular endothelial tissue to induce diabetes and hypertension.


ABC transporter
ATP binding domain
BPI11 domain


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.